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Summary. The term “probiotic” comes from the Greek “pro bios” and means “pro-life”. Nowadays, an increasing 
number of pharmaceutical preparations and functional foods are enriched with probiotics and for the patients 
it is increasingly important to receive the information needed to know how to orient in the choice. The benefits 
from probiotics are many and include the modulation of the intestinal microflora (stimulation of beneficial 
bacteria and inhibition of pathogens), the support of bowel function and the stimulation of the immune system. 
This broad spectrum of beneficial effects contributes to maintain efficient the intestinal ecosystem. Therefore, 
probiotics are an useful tool to prevent the formation of disorders and/or pathologies. The aim of this review is 
to describe the intestinal ecosystem and how probiotics could be effective in the treatment and prevention of 
possible alterations.
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Introduction
In recent years, the demand of health by healthy 
subjects increased in terms of quantity and quality. 
Patients increasingly informed and attentive to health 
and prevention issues go to their doctors for informa-
tion and decision-making aspects. Hence the need of 
general practitioners to acquire new skills as they play 
a key role in the application and dissemination of ap-
propriate prevention strategies.
The prevention and management of chronic dis-
eases by General Medicine play a key role in  popula-
tion health. One of the most important topic in pre-
vention is nutrition. Daily, general practitioners answer 
patients questions regarding their health and dispense 
nutrition advice.
In nutrition field, great attention has been paid to 
Mediterranean diet (1), but a new interesting topical is 
about “probiotics”. This term was coined many years ago 
but its definition has recently reached an international 
consensus, replacing the old term of “lactic ferments” 
which has been used for a long time. The lactic ferments 
indicated the bacteria responsible of lactic fermentation 
and it corresponded to the British term “Lactic Acid 
Bacteria”, which includes all bacteria that produce lactic 
acid from various substrates (eg. Lactobacilli, Strepto-
cocci, Lactococci). More than a century ago, the ben-
eficial effects of lactic acid bacteria were proposed by 
Nobel laureate Elias Metchinkoff in his book entitled 
“The prolongation of life” (2). Metchinkoff, based on 
his observations on the longevity of the Balkan peoples 
who consumed large amounts of yoghurth, assumed a 
beneficial protective effect of the bacterial flora in hu-
mans, as well as the lactic fermentation stopped the pu-
trefactive phenomena of food matrices (eg. milk, meat, 
vegetables) (2). This intuition found  the scientific vali-
The intestinal ecosystem and probiotics 9
dation many years later and the small number of con-
trolled clinical trials contributed to the persistence of a 
certain skepticism in the medical community about the 
clinical efficacy of probiotics, considered only placebo. 
In the last decade, many studies of molecular biology 
gave a better characterization of the bacterial species 
and their function; clinical trials of phase 2 and 3 in dif-
ferent clinical conditions have shown efficacy of strains 
with the characteristics required to be defined probiot-
ics. It is increasingly clear that the action of probiotics 
should not be seen only in clinical terms but must be 
assessed from the point of view of the beneficial effects 
on people’s health. 
The intestinal ecosystem
The term  intestinal ecosystem has recently been 
introduced in the medical field. This term indicates the 
functions and interactions between the mucosal barrier, 
the local immune system and the intestinal microflo-
ra. The intestinal microflora is considered a real organ 
metabolically active and very important for the health 
of our body.
To understand the importance of the bacterial 
flora  in the homeostasis of the organism it is necessary 
to know the extent and complexity of its composition, 
and the many activities and interactions that it per-
forms. In the intestine, there were identified to date up 
to 500 different species of bacteria with a total luminal 
contents of microbial cells about ten times higher than 
the number of somatic cells. In one gram of feces they 
can be isolated 100-200 billion of bacteria, whose mass 
is physiologically about 60% of the weight of feces (3).
The concentration of the bacterial flora varies along 
the digestive tract increasing exponentially in the oral- 
fecal-route. In the stomach and in the first section of the 
small intestine there is a low concentration of bacteria 
(101-104 per gram of content) mainly due to the pres-
ence of acid, bile and pancreatic juice which is not favor-
able for their development and propulsive motor activity 
that prevents stable colonization and pushes the contents 
of the lumen to the ileum. The bacterial concentration 
increases gradually along the intestine to reach 1011-
1012 microorganisms/g in the colon (Figure 1). The 
colonization of the intestinal lumen occurs during the 
birth and the initial pattern of bacteria is influenced by 
the type of childbirth, nutrition and social-environmen-
tal conditions. A few hours after birth aerobic bacteria 
begin to develop (coliforms, streptococci, lactobacilli, 
enterococci) and at 10-11 days of age Bacteroides ap-
pear. The latter are the main constituents of the bacterial 
flora which is outlined in 3-4 weeks of life and does not 
change significantly in normal conditions. So the initial 
colonization is crucial in determining the final composi-
tion of the intestinal microflora of the adult, which varies 
from individual to individual and remains constant dur-
ing life even if the concentration of the various species 
may temporarily vary in different pathological condi-
tions. The completed flora consists mainly of anaerobic 
microorganisms (eg. Bacteroides, Bifidobacterium, Eu-
bacterium, Clostridium, Peptostreptococcus, Strepto-
coccus) that are 100-1000 times more numerous than 
the aerobic (Escherichia, Enterobacter, Enterococcus, 
Klebsiella, Lactobacillus, Proteus, etc.).
Functions of the intestinal microflora
Numerous studies, performed primarily on animals 
sterile intestinal contents (germ-free), demonstrated 
the multiple activities of the intestinal flora, which are 
grouped in metabolic, trophic and protective functions. 
The most important metabolic function is  the diges-
tion (fermentation) of carbohydrates non-digestible by 
humans (cellulose, hemicellulose, pectins, gums, starch) 
by the bacterial enzymes, resulting in the production 
Figure 1. The intestinal Flora
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of short chain fatty acids (SCFA) and gases (H2, CO2, 
methane, hydrogen sulphide) (4). The SCFA are an en-
ergy source for the bacteria, for colonocytes and, once 
absorbed, for the somatic cells; moreover, they are in-
volved in the metabolism of sugars by improving insulin 
sensitivity, they acidify the intestinal environment (5) by 
preventing the proliferation of pathogenic germs (6), 
they increase the blood flow and the intestinal motility 
and promote the re-absorption of water and ions. The di-
gestion of peptides and proteins (7), such as elastin, food 
collagen, pancreatic enzymes, mucin, epithelial cells and 
bacteria lysates, leads also to the production of SCFA, 
but also potentially toxic substances, such as ammonia, 
amines, phenols, thiols, indoles and gases. Fermentation 
takes place primarily in the cecum and ascending colon 
where the environment is more acidic for the presence of 
saccarolitic flora in rapid growth. Rot is instead prevalent 
in the distal colon, where the flora is more static and the 
pH is closer to neutrality. Another metabolic activity of 
intestinal bacteria is the production of vitamins (panto-
thenic acid, biotin, pyridoxine, riboflavin), but it is still 
unknown how they are utilized by the body. The trophic 
function of the intestinal microflora (8) occurr through 
the proliferation and differentiation of epithelial cells 
(by SCFA) and through maturation and stimulation of 
the intestinal immune system (gut associated lymphoid 
tissue, GALT - about 25% of the intestinal mucosa). 
Many studies  highlighted the complex interaction be-
tween the bacterial flora and the GALT that is funda-
mentally important, already in the early stages of life, 
for the development of our immuno-regulatory system 
(6). The protective function operates mainly through a 
physical barrier that prevents the adesion and the tis-
sue penetration of pathogens and injurious substances. 
The protection mechanisms may include the competi-
tive binding with intestinal epithelial cell receptors, the 
competition in the use of substrates (space and food), 
the production of antimicrobial substances (bacterio-
cins, ammonium, H2O2) and the lowering of the luminal 
pH through the production of SCFA (9). The protective 
function is also expressed through immunomodulation 
with increase in the specific antibody response and the 
regulation of the production of pro- and anti-inflam-
matory cytokines. The immuno-surveillance monitors 
infections and immune-tolerance prevent the develop-
ment of allergies (10).
Alterations of the intestinal ecosystem
The maintenance of the intestinal ecosystem is 
based on the integrity and stable cooperation between 
the microflora, the immune system and the barrier 
formed by the intestinal mucosa. Any event that in-
tervene to alter each of these components creates an 
imbalance with the consequent onset of local and/or 
systemic diseases (11,12). It is very important the bal-
ance between the different species of the bacterial flora 
in which there are harmful bacteria (Pseudomonas aeru-
ginosa, bacteria belonging to the genera Staphylococcus, 
Clostridium, Proteus, Veillonella), protective bacteria 
that become harmful in particular conditions (Esch-
erichia coli, enterococci, streptococci, Bacteroides) and 
bacteria with protective action (belonging to the genera 
Lactobacillus, Bifidobacterium, Eubacterium) (13). The 
pathogenic strains are characterized by their ability to 
produce toxins, they could be invasive and produce sub-
stances with carcinogenic action; in health conditions 
their growth and their metabolic activities are inhibited 
by the protective flora. Table 1 lists some conditions 
that alter the composition of the intestinal microflora 
Table 1. Main causes of altered intestinal flora 
Anatomical alterations
Diverticula
Stenosis and obstruction
Motility alterations
Progressive systemic sclerosis
Diabetic neuropathy
Pseudo intestinal obstruction
Accelerated gastric emptying
Incontinence of ileocecal valve
Post-surgical  alterations
Ansa blind
Gastric and intestinal resections
Resection of ileocecal valve
Jejunum-ileal bypass 
Other conditions
Malnutrition
Immunodeficiency
Aging
Prolonged therapy with antisecretory (H2 blockers or PPIs)
Antibiotic therapy
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(10). Many of these conditions can also cause bacterial 
overgrowth in the first sections of the small intestine 
(duodenum and jejunum) with a clinical profile that is 
currently defined by the acronym SIBO (Small Intes-
tinal Bacterial Overgrowth). Alterations of the intes-
tinal flora could also occur during antibiotic therapies, 
with aging and with nutritional modifications. It is well 
known that there is a relationship between diet and the 
incidence of certain types of cancer, particularly colon 
cancer. A diet high in fat and red meat seems to be as-
sociated with a high risk of colorectal cancer and this 
carcinogenic effect could be mediated by the modifica-
tion of the intestinal microflora resulting in the selec-
tion of germs producing carcinogens (co-carcinogens or 
pro-carcinogens). Therefore, some bacteria can induce 
alterations in colonocytes  DNA by producing mol-
ecules such as heterocyclic amines, which instead may 
be removed by other bacteria (14). Some studies in ani-
mal models showed that bacteria belonging to the gen-
era Bacteroides and Clostridium increase the incidence 
and growth of tumors of the colon, whereas lactobacilli 
and bifido-bacteria, seem to prevent tumorigenesis (15). 
Lesions of the intestinal barrier may allow the passage 
of bacteria contained in the lumen through the mu-
cosa (generally aerobic gram-negative as Escherichia, 
Proteus, Klebsiella), a phenomenon called transloca-
tion. After passing through the mucosa, viable bacteria 
can reach the mesenteric lymph nodes, spleen and liver 
through the lymphatic vessels and then disseminate in 
the organism causing sepsis.
In healthy subjects, it is believed that the positiv-
ity of the culture of the mesenteric lymph nodes does 
not exceed 5%, while it rises to 15-40% in diseases 
such as multiple organ failure, severe acute pancre-
atitis, advanced liver cirrhosis, intestinal obstruction, 
chronic inflammatory bowel diseases (16-18).
Translocation was described in patients under-
going laparotomy, in the post-operative sepsis, in 
spontaneous bacterial peritonitis in patients with liver 
cirrhosis. The lesions of the intestinal wall are a fre-
quent feature of inflammatory bowel disease (such as 
ulcerative colitis, Crohn’s disease), whose etiology to 
date is still unknown. Although the infectious origin 
of these diseases remains for now just one of the hy-
potheses, numerous studies showed that the intestinal 
flora contributes to the development and maintenance 
of inflammation; for this reason, current studies aim 
to evaluate the effect of probiotics in the treatment of 
these diseases (18).
Probiotics: definitions and properties
Probiotics are defined as “live and vital microor-
ganisms that confer health benefits when consumed in 
adequate amounts, as part of a food or a supplement”. 
It is important to distinguish them from “prebiotics”, 
which indicate the non-absorbed food components that 
stimulate the growth of one or more protective bacteria 
of the intestinal flora and, in this way, it makes a positive 
effect on human health. In addiction,”symbiotic” means 
the combined administration of specific probiotics with 
prebiotics to determine benefits through a synergic ac-
tion of the two components (19). The authorization 
for the use of probiotics is now based on the respect 
of the criteria defined by the  international guidelines 
(20) which include identification, safety, efficacy. It is 
important to consider that the probiotic properties are 
the characteristics of the single strain studied and it can 
not be extended to other bacteria, even if they belong to 
the same species. Regarding the other criteria, the in vi-
tro and in vivo tests are needed to determinate the safety 
and functional characteristics required for a probiotic: 
resistance to gastric acid and bile, adhesion to mucus 
and/or intestinal cells, antimicrobial activity against 
pathogenic strains, reduction of the adesion of patho-
gens, hydrolysis  of bile salts, resistance to spermicides 
(for probiotics used in the vagina).
The certification of the safety of probiotics is nec-
essary to prevent the occurrence of any systemic infec-
tions, harmful metabolic activities, excessive immune 
stimulation, gene transfer. The bacterial genera most 
used and studied (Lactobacillus and Bifidobacterium) 
are the prrof of safety as they are common commensals 
of human microflora and they are used for the fermen-
tation of many foods. There are very few reported cases 
so far, in which it can be assumed that the probiotic, 
added to the diet, has given rise to intestinal infec-
tions, and they are all described in debilitated patients 
exposed to extensive antibiotic therapies (20).
Probiotics are those bacteria that regulate actions 
and processes that take place in the bowel (digestion, 
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immune defense, defense bacteriological etc.) and ac-
tion of welfare. The word was coined about 50 years ago 
and it has had several changes over the years, but in this 
context it seems appropriate to refer to the one adopted 
in December 2005 by the Ministry of Health: “probiot-
ics are live microorganisms and vital that confer health 
benefits when consumed in adequate amounts, as part 
of a food or a nutritional supplement. This definition is 
similar to that provided by  FAO/WHO in 2002 and 
then also reflected in the world (20) .
The guidelines that define what probiotics are, tak-
en by international organizations and by Italian Minis-
try of Health, consider the correct identification of the 
bacterial strain, the effective dose, the safety and efficacy. 
Regarding identification, bacteria are so many and they 
are different from each other; even those they belong 
to the same “bacteria family”. The bacteria species are 
identified by the use of Latin and the two names genre + 
species (for example in the name Lactobacillus casei, the 
first term indicates the bacterial genus, while the sec-
ond specify which the specie is). We could compare the 
bacterial species to the family and the genre to the clan. 
The ability to be probiotic is a property of the strain and 
within a specie, not all the strains are probiotics. There-
fore it is crucial, both in scientific studies and in com-
mercial products, that it is indicated the probiotic strain 
to which it refers, and not just the specie (eg Lactobacil-
lus casei Shirota, or Bifidobacterium lactis BB12). The 
effective dose, that is the amount of live and vital bac-
terial cells for administration to an individual needed 
to express probiotic properties, is definitely an essential 
point to be determined. Safety must be demonstrated 
in vitro and in vivo in animals. Most of the currently 
known probiotic organisms are included in the GRAS 
list (Generally Recognized As Safe) and therefore their 
use is considered safe. The effectiveness of a probiotic 
strain is assessed by in vivo tests, during the volunteers 
consume the product under medical supervision and it 
is then subjected to specific tests (for example, the pro-
file of immune cells) (20). 
Functional probiotic foods
A functional food can thus be a natural food or it 
can be a food that has been modified to have a func-
tional influence on the health and well-being of the 
consumer through the addition, removal, or modifica-
tion of specific components (21).
A typical characteristic of probiotic bacteria is 
their ability to arrive alive and active in the colon in 
high quantities. As far as probiotics are in foods, it nec-
essarily implies that they have to overcome the gastric 
barrier and tolerate the presence of bile acids in such a 
way as to arrive alive in the intestine in much greater 
amounts than those found for the bacteria normally 
used in the production of yoghurt. To be considered 
probiotic, a bacterium must therefore be able to have 
scientific studies which demonstrate the vitality in the 
human gut and the ability to play a positive activity to 
the consumer (22). 
Dairy-related functional foods include yogurt and 
other fermented dairy products. Various species of lac-
tobacilli and bifidobacteria are used in the production 
of fermented milk products.
These live microorganisms  have been reported 
to have several beneficial effects, including aiding the 
prevention of cancer and hypertension, as well as ther-
apeutic effects on intestinal tract function, immune 
function, and stomach health (23). The cancer-pre-
venting mechanism of probiotics is reportedly related 
to their byoproducts, which might decrease cancer 
cell proliferation (24) Furthermore, probiotics might 
improve symptoms of lactose intolerance and reduce 
serum cholesterol (25).
The strain Lactobacillus casei Shirota (LcS) has 
been the subject of scientific research to prove its pro-
biotic properties and safety of its use for more than 70 
years.
In vitro it has been observed that LcS is able 
to tolerate the gastric fluids and the presence of so-
dium deoxycholate better than other strains used for 
the production of yoghurth (26). A recent study re-
ports the presence of the strain LcS in the faeces of 
healthy volunteers after three weeks of daily intake of 
fermented milk containing 6.5 billion this bacterium 
(27). This result shows that this strain can tolerate the 
passage through the stomach and it can reach the in-
testines alive and active, critical prerequisite for defin-
ing a bacterial strain probiotic . It was noted that LcS 
does not adhere permanently to the intestinal walls 
and therefore, 2-3 weeks after the last dose, it is no 
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longer isolated from feces (28). This suggests the need 
to continue restoring the probiotic every day in order 
to keep it in sufficiently high amounts within the gut.
Numerous scientific studies, in vitro, in animals 
but also in clinical studies attest the ability of this strain 
to bring many benefits to the body, by the modulation 
of the intestinal microflora, the functionality of the in-
testine and the stimulation of certain immune system 
activity (eg. Natural Killer cells activity ) (29-35).
Omega-3 fatty acids, which are an important 
functional component and essential fatty acid of ani-
mal origin, are mainly found in fatty fish. The two pri-
mary n-3 fatty acids are eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA),26 and these fatty 
acids have been reported to reduce the risk of coro-
nary heart disease (36), cardiac deaths, and fatal and 
non-fatal myocardial infarction, as well as to reduce 
triglycerides (37). In addition to the natural sources 
of n-3 fatty acids, such as fatty fishes like salmon, 
tuna, and sardines, several commercial food products 
are now fortified with n-3 fatty acids. Some examples 
of commercially available n-3-fortified foods include 
eggs, milk, mayonnaises, margarines, and salad dress-
ings (38).
Red wine contains phenolic compounds, and it 
could be considered as a functional food. Phenolic 
compounds have been reported to have antioxidant ef-
fects and might prevent the oxidation of low-density 
lipoprotein (LDL) (39). Wine drinking has also been 
linked to the reduction of certain cancers (40).
Soy protein has many significant health benefits 
for humans, such as lowering the levels of total and 
LDL cholesterol in the blood and reducing the risk of 
certain cancers. The US Food and Drug Administra-
tion (FDA) has also reported that daily consumption 
of 25 g of soy protein, coupled with a low-cholesterol 
diet,might reduce the risk of heart disease (37).
Coronary heart disease (CHD) is related with 
the level of cholesterol in the serum (41). Plant sterols 
(phytosterols) influence the serum cholesterol level by 
inhibiting absorption of cholesterol and LDL choles-
terol (42). 
Plant sterols can be obtained from fruits and 
vegetables; however, such foods contain only small 
amounts of phytosterols. 54 Nuts and vegetable oils 
contain higher amounts of phytosterols than fruits and 
vegetables (43). In addition to these foods, food mar-
kets offer plant sterolenriched
foods, like spreads or drinks. The FDA has re-
ported that a daily intake of at least 1.3 g of plant ste-
rols might reduce the risk of heart disease (37). 
Consumption of whole grains and cereals are 
known to improve digestion due to their high fiber 
content. In addition, the endosperm of whole grains 
contains bran and germs that are rich in micronutri-
ents and phytochemicals (44).  It has been reported 
that consumption of whole grains might reduce the 
risk of heart disease, type 2 diabetes mellitus, and vari-
ous types of cancer (45).
Another fiber-rich food group is fruits and veg-
etables – a group that also contains many vitamins and 
nutrients beneficial for health. The FDA has reported 
that consumption of fiber-rich
foods, like grains or fruits and vegetables, when 
coupled with a low-fat diet,might reduce the risk of 
some types of cancer, and intake of soluble fiber in 
which grains, vegetables, and fruits are rich, might re-
duce the risk of heart disease (37).
Clinical applications
Data from in vitro studies should be followed by 
the evaluation of effectiveness and usefulness in vivo. 
Also in vivo, in healthy volunteers, the effective dose can 
be determined, the quantity of live and vital bacterial 
cells for administration to an individual so that they can 
express probiotic properties. The works published in the 
last five years show a number of beneficial effects on the 
human body provided by probiotics (Table 2).
Proven benefits of probiotics include the treat-
ment of acute (46) and antibiotic-associated diarrhea 
(47); applications with substantial evidence include 
the prevention of atopic eczema and traveler’s diar-
rhea (48); promising applications include the preven-
tion of respiratory infections in children, prevention 
of dental caries (49,50), elimination of nasal pathogen 
carriage, prevention of relapsing C. difficile–induced 
gastroenteritis, and treatment of inflammatory bowel 
disease (51); and proposed future applications include 
the treatment of rheumatoid arthritis (52), treatment 
of irritable bowel syndrome, cancer prevention, pre-
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vention of ethanol-induced liver disease, treatment of 
diabetes, and prevention or treatment of graft-versus-
host disease. The use of probiotics in medical practice 
is rapidly increasing, as are studies that demonstrate 
the efficacy of probiotics (51).
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